Concepedia

Palbociclib in Patients With Pancreatic and Biliary Cancer With<i>CDKN2A</i>Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett‐Mayer, Pam K. Mangat, Eugene R. Ahn, Vaibhav Sahai, Ricardo H. Álvarez, Edward S. Kim, Kathleen J. Yost, Andrew L. Rygiel,

JCO Precision Oncology · 2019 · 90 citations · 25 references

DOI

Abstract

Palbociclib monotherapy does not have clinical activity in patients with advanced pancreatic or biliary cancers with <i>CDKN2A</i> loss or mutation. Toxicity is similar to reported experience with palbociclib in other tumor types.

References

25

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.5K citations

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

Juan W. Valle, Harpreet Wasan, Daniel H. Palmer et al. · New England Journal of Medicine · 2010 · 4.3K citations · Full text

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.8K citations

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

, , +11